This is not the most recent version of the article. View current version (24 JAN 2007)

Intervention Review

Amantadine for fatigue in multiple sclerosis

  1. C Taus,
  2. A Solari,
  3. R D'Amico,
  4. P Branãs,
  5. C Hyde,
  6. G Giuliani,
  7. E Pucci

Editorial Group: Cochrane Multiple Sclerosis Group

Published Online: 22 APR 2003

DOI: 10.1002/14651858.CD002818

How to Cite

Taus C, Solari A, D'Amico R, Branãs P, Hyde C, Giuliani G, Pucci E. Amantadine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD002818. DOI: 10.1002/14651858.CD002818.

Author Information

*Dr Cristiana Taus, Neurologist, Unità Operativa di neurologia, Ospedale San Salvatore, Piazzale Cinelli,4, Pesaro, ITALY. cristianataus@yahoo.it.

Publication History

  1. Published Online: 22 APR 2003

SEARCH

This is not the most recent version of the article. View current version (24 JAN 2007)

 

Abstract

  1. Top of page
  2. Abstract
  3. Synopsis

Background

Fatigue is one of the most common and disabling symptoms of people with Multiple Sclerosis (MS). The effective management of fatigue has an important impact on the patient's functioning, abilities, and quality of life. Although a number of strategies have been devised for reducing fatigue, treatment recommendations are based on a limited amount of scientific evidence. Many textbooks report amantadine as a first-choice drug for MS-related fatigue because of published randomised controlled trials (RCTs) showing some benefit. We performed a systematic review in order to gather existing evidence, and contribute to the topic.

Objectives

To determine the effectiveness and safety of amantadine in reducing fatigue in people with MS.

Search strategy

We searched MEDLINE (January 1966 to May 2002), EMBASE (1988 to May 2002), bibliographies of relevant articles and handsearched relevant journals. We also contacted drug companies and researchers in the field.

Selection criteria

Randomised, placebo or other drugs-controlled, double-blind trials of amantadine in MS people with fatigue.

Data collection and analysis

Three reviewers selected studies for inclusion in the review and they extracted the data reported in the original articles. We requested missing and unclear data by correspondence with the trial's principal investigator. A meta-analysis was not performed due to the inadequacy of available data, heterogeneity of outcome measures.

Main results

Out of twelve pertinent publications, four trials met the criteria for inclusion in this review: one study was a parallel arms study, and three were crossover trials. The number of randomised participants ranged between 10 and 115, and a total of 236 MS patients were studied. Overall the quality of the studies considered was poor and all trials were open to bias. All studies reported small and inconsistent improvements in fatigue, whereas the clinical relevance of these findings and the impact on patient's functioning and health related quality of life remained undetermined. The number of participants reporting side effects during amantadine therapy ranged from 10% to 57%, without significant differences between treatment and placebo. The side effects reported were generally mild, and discontinuation of the drug due to side effects occurred in less than 10% of the patients.

Authors' conclusions

Amantadine treatment is generally well tolerated, however its efficacy in reducing fatigue in people with MS is poorly documented. It is advisable to: (1) improve knowledge on the underlying mechanisms of MS-related fatigue; (2) achieve an agreement on accurate, reliable and responsive outcome measures of fatigue; (3) perform good quality RCTs.

 

Synopsis

  1. Top of page
  2. Abstract
  3. Synopsis

Plain language summary

More research is needed into the effect of Amantadine for fatigue for people with multiple sclerosis

Multiple sclerosis (MS) is a chronic disease affecting young and middle-aged adults. One of the most common and disabling symptoms of MS is fatigue. Different approaches have been used to try and improve this, including energy conservation, specialised fitness training and drug treatments. Amantadine is an antiviral drug which has been used to try to relieve fatigue in MS. This review found that Amantadine treatment is well tolerated, however its efficacy in reducing fatigue in people with MS is poorly documented and more research is needed.